BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7630151)

  • 1. Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits.
    Zhang J; Pfaffendorf M; van Zwieten PA
    J Cardiovasc Pharmacol; 1995 May; 25(5):724-31. PubMed ID: 7630151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of various angiotensin receptor antagonists on cardiovascular responses to angiotensin II in pithed rats.
    Zhang J; Pfaffendorf M; van Zwieten PA
    J Cardiovasc Pharmacol; 1994 Jul; 24(1):108-13. PubMed ID: 7521474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists.
    Zhang J; Entzeroth M; Wienen W; Van Meel JC
    Eur J Pharmacol; 1992 Jul; 218(1):35-41. PubMed ID: 1397034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive inotropic action of angiotensin II in the pithed rat.
    Zhang J; Pfaffendorf M; van Zwieten PA
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Jun; 347(6):658-63. PubMed ID: 8103195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria.
    Li Q; Zhang J; Pfaffendorf M; van Zwieten PA
    Br J Pharmacol; 1996 Aug; 118(7):1653-8. PubMed ID: 8842428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive activity of the novel, nonpeptide angiotensin II receptor antagonists BIBS 39 and BIBS 222 in conscious renal hypertensive rats.
    Zhang J; Van Meel JC; Van Zwieten PA
    Pharmacology; 1993 May; 46(5):241-7. PubMed ID: 8488169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
    Li Q; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2001 Apr; 15(2):143-50. PubMed ID: 11468024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
    Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog.
    Clark KL; Robertson MJ; Drew GM
    Br J Pharmacol; 1993 May; 109(1):148-56. PubMed ID: 8495237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
    Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
    Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW; Widdop RE
    Br J Pharmacol; 1995 Dec; 116(8):3181-90. PubMed ID: 8719794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KT3-671, an angiotensin AT1 receptor antagonist, attenuates vascular but not cardiac responses to sympathetic nerve stimulation in pithed rats.
    Takata Y; Kurihara J; Yoda T; Suzuki S; Matsuoka Y; Okubo Y; Kato H
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):427-36. PubMed ID: 11300656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2-receptor antagonists given after the AT1-receptor antagonist, EXP 3174.
    Widdop RE; Gardiner SM; Kemp PA; Bennett T
    Br J Pharmacol; 1992 Nov; 107(3):873-80. PubMed ID: 1472980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens; 2001 Dec; 19(12):2241-50. PubMed ID: 11725169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).
    Wong PC; Hart SD; Zaspel AM; Chiu AT; Ardecky RJ; Smith RD; Timmermans PB
    J Pharmacol Exp Ther; 1990 Nov; 255(2):584-92. PubMed ID: 2243344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.
    Picard P; Chrétien L; Couture R
    Br J Pharmacol; 1995 Apr; 114(8):1563-70. PubMed ID: 7541280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
    Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
    Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.